Provided by Tiger Fintech (Singapore) Pte. Ltd.

Leap Therapeutics Inc

0.3999
+0.00681.73%
Post-market: 0.40000.0001+0.03%19:56 EDT
Volume:342.41K
Turnover:135.49K
Market Cap:16.50M
PE:-0.22
High:0.4000
Open:0.3931
Low:0.3800
Close:0.3931
Loading ...

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

PR Newswire
·
26 Apr

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

PR Newswire
·
15 Apr

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Benzinga
·
27 Mar

Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial

MT Newswires Live
·
26 Mar

BRIEF-Leap Therapeutics Reports Fourth Quarter And FY 2024 Results

Reuters
·
26 Mar

Leap Therapeutics Q4 Operating Expenses USD 16.125 Million

THOMSON REUTERS
·
26 Mar

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

PR Newswire
·
26 Mar

Leap Therapeutics Reports Positive Updated Data From Sirexatamab Colorectal Cancer Study

THOMSON REUTERS
·
26 Mar

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

PR Newswire
·
26 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

Leap Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
21 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
20 Mar

Leap Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
14 Mar

Leap Therapeutics Shares Tumble After Downgrades from Baird, HC Wainwright

MT Newswires Live
·
30 Jan

Baird Downgrades Leap Therapeutics to Neutral From Outperform, Cuts Price Target to $1.25 From $9

MT Newswires Live
·
29 Jan

HC Wainwright Downgrades Leap Therapeutics to Neutral From Buy

MT Newswires Live
·
29 Jan

Leap Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
29 Jan

Leap Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
29 Jan

U.S. RESEARCH ROUNDUP-Apple, Coinbase Global, Nextracker

Reuters
·
29 Jan

Leap Therapeutics Inc : Baird Cuts to Neutral Rating; Cuts Target Price to $1.25 From $9

THOMSON REUTERS
·
29 Jan